Kidney Stone Retrieval Devices Market by Product Type (Lithotripters, Stone Removal Baskets, Ureteral Stents), Treatment (Extracorporeal Shock Wave Lithotripsy, Percutaneous Nephrolithotomy, Ureteroscopy), Treatment Modality, Stone Type, End User, Distrib
Description
The Kidney Stone Retrieval Devices Market was valued at USD 2.36 billion in 2024 and is projected to grow to USD 2.50 billion in 2025, with a CAGR of 5.85%, reaching USD 3.73 billion by 2032.
Strategic introduction to the kidney stone retrieval field emphasizing clinical drivers, technological innovation, regulatory shifts, and patient expectations influencing device adoption
The contemporary landscape of kidney stone retrieval devices is defined by rapid technological refinement, shifting clinical protocols, and growing patient expectations for less invasive care. Clinicians are increasingly focused on devices that balance precise stone clearance with minimized tissue trauma and faster recovery times, and manufacturers are responding with innovations in endoscope optics, flexible ureteroscope durability, and adjunctive stone fragmentation systems. Concurrently, healthcare providers are optimizing procedural workflows to reduce operating room time and post-procedural complications, which in turn influences device selection and purchasing priorities.
Patients and payers are driving demand for procedures that offer predictable outcomes with lower length of stay, and this expectation is reshaping how device developers prioritize ease of use, sterilization efficiency, and device longevity. At the same time, regulatory bodies are applying more stringent post-market surveillance requirements, prompting suppliers to invest in real-world evidence generation and enhanced device traceability. Taken together, these forces are accelerating a transition toward integrated procedural platforms that combine visualization, fragmentation, and retrieval capabilities while enabling clinicians to tailor interventions by stone composition, size, and anatomical location.
Compelling overview of transformative clinical and technological shifts reshaping device development, delivery models, and competitive advantage in stone retrieval
Several transformative shifts are redefining competitive dynamics and clinical practice in kidney stone retrieval. First, the maturation of flexible ureteroscopes with improved deflection and digital imaging has enabled more widespread treatment of complex intrarenal stones without resorting to open surgery. Second, advancements in lithotripsy energy delivery and laser fiber technologies have improved fragmentation efficiency, allowing for finer control of stone comminution and reducing the need for auxiliary procedures. Third, the emphasis on ambulatory care has incentivized device designs that support same-day discharge and simplified sterilization pathways, making some treatments more accessible outside of traditional hospital settings.
Additionally, the convergence of data analytics and connected devices is beginning to influence product development cycles; manufacturers that can demonstrate device performance through clinical registries and post-market data will gain a competitive advantage. Furthermore, supply chain resilience and modular component strategies are becoming essential as providers seek reliable access to single-use and reusable instruments. In sum, the landscape is shifting toward minimally invasive, evidence-backed solutions supported by robust data, streamlined logistics, and designs optimized for outpatient environments.
In-depth assessment of how evolving United States tariff policies are influencing supply chain strategies, procurement decisions, and cost structures across the kidney stone device value chain
The tariff environment in the United States has introduced a layer of complexity for manufacturers, distributors, and healthcare providers that rely on cross-border sourcing of components, capital equipment, and disposables. Changes in import duties and customs procedures have the potential to increase landed costs for critical components such as optical assemblies, laser modules, and specialized polymers used in single-use devices. As a result, procurement teams are reassessing supplier footprints and evaluating nearshoring options to mitigate exposure to tariff volatility and customs delays.
In response, several manufacturers are recalibrating supply chains to prioritize diversified sourcing, regional distribution hubs, and localized assembly where feasible. These adjustments aim to reduce lead times, protect margins, and preserve price competitiveness for end-users. Simultaneously, healthcare systems are scrutinizing total cost of ownership more closely, considering not only unit price but also availability, service contracts, and device longevity. Thus, tariff-driven dynamics are accelerating strategic decisions around supplier relationships, inventory policy, and capital procurement timing to maintain continuity of care and manage operating budgets.
Comprehensive segmentation insights revealing how product types, treatment approaches, procedural modalities, stone composition, end-user settings, and distribution channels drive decision-making
Segmentation offers a multifaceted lens for understanding product development priorities, clinical adoption pathways, and procurement behaviors. When examining the field based on product type, attention falls on Lithotripters, Stone Removal Baskets, Ureteral Stents, and Ureteroscopes, each of which plays a distinct role in procedural algorithms and influences capital planning and disposable usage. Looking through the treatment prism reveals how Extracorporeal Shock Wave Lithotripsy, Percutaneous Nephrolithotomy, and Ureteroscopy generate different device utilization patterns, clinical competencies, and facility requirements that inform training and investment decisions.
Considering treatment modality, the delineation among Minimally Invasive Procedures, Non-Invasive Procedures, and Open/Conventional Surgeries highlights the movement toward less invasive approaches and the corresponding demand for instruments that support precision and efficiency. Stone composition also impacts device selection; Calcium Stones, Cystine Stones, Struvite Stones, and Uric Acid Stones each respond differently to fragmentation methods and retrieval techniques, which clinicians must weigh when planning interventions. Finally, end-user segmentation clarifies purchasing cycles and use environments by distinguishing Ambulatory Surgical Centers, Clinics, and Hospitals, while distribution channel dynamics across Offline and Online pathways affect procurement velocity, service expectations, and product support models. Together, these segmentation perspectives reveal where innovation will most likely yield clinical benefit and commercial traction.
Targeted regional perspectives exploring how the Americas, Europe Middle East & Africa, and Asia-Pacific present distinct clinical, regulatory, and commercial opportunities for device suppliers
Regional dynamics shape clinical adoption, reimbursement policies, and supplier strategies in distinct ways. In the Americas, clinical practice patterns and the growing ambulatory care infrastructure are encouraging the wider use of minimally invasive devices, with an emphasis on integrating durable reusable platforms and cost-efficient disposables that support high procedural throughput. Reimbursement and coding nuances also influence which treatments are most commercially viable in different payer contexts, which in turn guides supplier go-to-market approaches.
Across Europe, Middle East & Africa, variable regulatory frameworks and infrastructure heterogeneity mean that suppliers must offer flexible product configurations, robust training programs, and adaptable service models to achieve traction. In many markets within this region, investment in diagnostic capability and procedural training is an important determinant of device adoption. In the Asia-Pacific region, rising healthcare spending, expanding ambulatory networks, and an active medical device innovation ecosystem are driving rapid uptake of newer technologies, particularly where cost-effectiveness and scalability align with national healthcare priorities. Consequently, manufacturers often pursue differentiated strategies across these regions-balancing direct sales, distributor partnerships, and localized support-to align with clinical, regulatory, and economic realities.
Insightful assessment of company strategies and competitive differentiators emphasizing innovation, clinical evidence generation, and lifecycle support across the device ecosystem
Competitive positioning in this sector depends on a blend of technological leadership, clinical evidence generation, and comprehensive post-sale service. Leading device manufacturers are investing in product enhancements that improve visualization, maneuverability, and fragmentation efficiency while reducing procedural complexity. At the same time, strategic alliances between equipment suppliers and academic centers are producing the real-world evidence necessary to support device claims and foster clinician confidence. Companies that maintain robust training programs and rapid service response capabilities strengthen their relationships with high-volume centers and ambulatory surgical facilities.
Additionally, differentiation is emerging through lifecycle support offerings, such as consumable supply assurance, preventative maintenance plans, and digital platforms that track utilization and outcomes. New entrants that bring disruptive materials or single-use solutions must demonstrate clear clinical and economic advantages to overcome incumbent familiarity and existing service contracts. In this environment, successful players will be those that combine product innovation with demonstrable clinical value and a dependable customer experience across procurement, training, and maintenance channels.
Actionable recommendations for manufacturers and healthcare providers to align innovation, supply resilience, clinical evidence, and service models to accelerate adoption and reduce risk
Industry leaders should pursue a coordinated approach that aligns product innovation with pragmatic commercialization and supply resilience. First, accelerating investments in minimally invasive visualization and fragmentation technologies will address clinician demand for precision and reduced procedure times while supporting outpatient care pathways. Second, building regional supply chain redundancy and exploring nearshore assembly or local partnerships can mitigate tariff and logistics risks, preserving continuity for high-volume customers. Third, prioritizing clinical evidence generation through registries and post-market studies will strengthen adoption and reimbursement discussions, and it will also create defensible differentiation that supports premium pricing.
Furthermore, companies should expand their service footprints to include integrated training, remote support, and predictive maintenance offerings that reduce downtime for end-users. Commercial teams must also refine channel strategies to balance direct relationships with distributors and to leverage online procurement platforms where appropriate, ensuring rapid replenishment and transparent pricing. Finally, aligning product portfolios to the specific needs of Ambulatory Surgical Centers, Clinics, and Hospitals-while accounting for stone-type treatment differences and procedure modality preferences-will enable more targeted sales and marketing investments and improve customer retention.
Transparent research methodology detailing how primary interviews, clinical literature review, device specification analysis, and expert validation were combined to inform findings
The research underpinning this analysis combined primary and secondary methods to ensure balanced, evidence-based conclusions. Primary inputs included structured interviews with practicing urologists, device procurement managers, and clinical engineers to capture firsthand perspectives on device performance, procedural preferences, and procurement constraints. These qualitative insights were triangulated with secondary sources, such as peer-reviewed clinical literature, regulatory filings, and publicly available health system procurement policies, to validate trends and identify emerging areas of clinical interest.
Analysts also examined device specifications, product roadmaps, and patent data to assess technological trajectories. Where possible, real-world clinical outcomes and post-market safety communications were reviewed to understand performance in diverse care settings. Throughout the process, emphasis was placed on ensuring data integrity and avoiding single-source dependency, and findings were iteratively reviewed by clinical advisors to ensure practical relevance and methodological rigor.
Concluding synthesis of how clinical innovation, care model evolution, and operational resilience converge to define future success in kidney stone retrieval
In conclusion, the kidney stone retrieval landscape is undergoing a steady evolution driven by a combination of technological refinement, shifting care models, and heightened expectations for efficiency and patient outcomes. Innovations in ureteroscope design, laser and lithotripsy modalities, and adjunctive retrieval tools are enabling clinicians to treat increasingly complex stone burdens with lower morbidity. Meanwhile, healthcare providers and payers are prioritizing solutions that support same-day care, predictable outcomes, and manageable service requirements.
Looking ahead, success for device manufacturers and health systems will depend on aligning product design with clinician workflow, investing in credible clinical evidence, and building resilient supply chains that can adapt to regional policy shifts and tariff pressures. Organizations that execute on these dimensions while maintaining a relentless focus on customer support and total procedural value will be best positioned to lead in this evolving environment.
Note: PDF & Excel + Online Access - 1 Year
Strategic introduction to the kidney stone retrieval field emphasizing clinical drivers, technological innovation, regulatory shifts, and patient expectations influencing device adoption
The contemporary landscape of kidney stone retrieval devices is defined by rapid technological refinement, shifting clinical protocols, and growing patient expectations for less invasive care. Clinicians are increasingly focused on devices that balance precise stone clearance with minimized tissue trauma and faster recovery times, and manufacturers are responding with innovations in endoscope optics, flexible ureteroscope durability, and adjunctive stone fragmentation systems. Concurrently, healthcare providers are optimizing procedural workflows to reduce operating room time and post-procedural complications, which in turn influences device selection and purchasing priorities.
Patients and payers are driving demand for procedures that offer predictable outcomes with lower length of stay, and this expectation is reshaping how device developers prioritize ease of use, sterilization efficiency, and device longevity. At the same time, regulatory bodies are applying more stringent post-market surveillance requirements, prompting suppliers to invest in real-world evidence generation and enhanced device traceability. Taken together, these forces are accelerating a transition toward integrated procedural platforms that combine visualization, fragmentation, and retrieval capabilities while enabling clinicians to tailor interventions by stone composition, size, and anatomical location.
Compelling overview of transformative clinical and technological shifts reshaping device development, delivery models, and competitive advantage in stone retrieval
Several transformative shifts are redefining competitive dynamics and clinical practice in kidney stone retrieval. First, the maturation of flexible ureteroscopes with improved deflection and digital imaging has enabled more widespread treatment of complex intrarenal stones without resorting to open surgery. Second, advancements in lithotripsy energy delivery and laser fiber technologies have improved fragmentation efficiency, allowing for finer control of stone comminution and reducing the need for auxiliary procedures. Third, the emphasis on ambulatory care has incentivized device designs that support same-day discharge and simplified sterilization pathways, making some treatments more accessible outside of traditional hospital settings.
Additionally, the convergence of data analytics and connected devices is beginning to influence product development cycles; manufacturers that can demonstrate device performance through clinical registries and post-market data will gain a competitive advantage. Furthermore, supply chain resilience and modular component strategies are becoming essential as providers seek reliable access to single-use and reusable instruments. In sum, the landscape is shifting toward minimally invasive, evidence-backed solutions supported by robust data, streamlined logistics, and designs optimized for outpatient environments.
In-depth assessment of how evolving United States tariff policies are influencing supply chain strategies, procurement decisions, and cost structures across the kidney stone device value chain
The tariff environment in the United States has introduced a layer of complexity for manufacturers, distributors, and healthcare providers that rely on cross-border sourcing of components, capital equipment, and disposables. Changes in import duties and customs procedures have the potential to increase landed costs for critical components such as optical assemblies, laser modules, and specialized polymers used in single-use devices. As a result, procurement teams are reassessing supplier footprints and evaluating nearshoring options to mitigate exposure to tariff volatility and customs delays.
In response, several manufacturers are recalibrating supply chains to prioritize diversified sourcing, regional distribution hubs, and localized assembly where feasible. These adjustments aim to reduce lead times, protect margins, and preserve price competitiveness for end-users. Simultaneously, healthcare systems are scrutinizing total cost of ownership more closely, considering not only unit price but also availability, service contracts, and device longevity. Thus, tariff-driven dynamics are accelerating strategic decisions around supplier relationships, inventory policy, and capital procurement timing to maintain continuity of care and manage operating budgets.
Comprehensive segmentation insights revealing how product types, treatment approaches, procedural modalities, stone composition, end-user settings, and distribution channels drive decision-making
Segmentation offers a multifaceted lens for understanding product development priorities, clinical adoption pathways, and procurement behaviors. When examining the field based on product type, attention falls on Lithotripters, Stone Removal Baskets, Ureteral Stents, and Ureteroscopes, each of which plays a distinct role in procedural algorithms and influences capital planning and disposable usage. Looking through the treatment prism reveals how Extracorporeal Shock Wave Lithotripsy, Percutaneous Nephrolithotomy, and Ureteroscopy generate different device utilization patterns, clinical competencies, and facility requirements that inform training and investment decisions.
Considering treatment modality, the delineation among Minimally Invasive Procedures, Non-Invasive Procedures, and Open/Conventional Surgeries highlights the movement toward less invasive approaches and the corresponding demand for instruments that support precision and efficiency. Stone composition also impacts device selection; Calcium Stones, Cystine Stones, Struvite Stones, and Uric Acid Stones each respond differently to fragmentation methods and retrieval techniques, which clinicians must weigh when planning interventions. Finally, end-user segmentation clarifies purchasing cycles and use environments by distinguishing Ambulatory Surgical Centers, Clinics, and Hospitals, while distribution channel dynamics across Offline and Online pathways affect procurement velocity, service expectations, and product support models. Together, these segmentation perspectives reveal where innovation will most likely yield clinical benefit and commercial traction.
Targeted regional perspectives exploring how the Americas, Europe Middle East & Africa, and Asia-Pacific present distinct clinical, regulatory, and commercial opportunities for device suppliers
Regional dynamics shape clinical adoption, reimbursement policies, and supplier strategies in distinct ways. In the Americas, clinical practice patterns and the growing ambulatory care infrastructure are encouraging the wider use of minimally invasive devices, with an emphasis on integrating durable reusable platforms and cost-efficient disposables that support high procedural throughput. Reimbursement and coding nuances also influence which treatments are most commercially viable in different payer contexts, which in turn guides supplier go-to-market approaches.
Across Europe, Middle East & Africa, variable regulatory frameworks and infrastructure heterogeneity mean that suppliers must offer flexible product configurations, robust training programs, and adaptable service models to achieve traction. In many markets within this region, investment in diagnostic capability and procedural training is an important determinant of device adoption. In the Asia-Pacific region, rising healthcare spending, expanding ambulatory networks, and an active medical device innovation ecosystem are driving rapid uptake of newer technologies, particularly where cost-effectiveness and scalability align with national healthcare priorities. Consequently, manufacturers often pursue differentiated strategies across these regions-balancing direct sales, distributor partnerships, and localized support-to align with clinical, regulatory, and economic realities.
Insightful assessment of company strategies and competitive differentiators emphasizing innovation, clinical evidence generation, and lifecycle support across the device ecosystem
Competitive positioning in this sector depends on a blend of technological leadership, clinical evidence generation, and comprehensive post-sale service. Leading device manufacturers are investing in product enhancements that improve visualization, maneuverability, and fragmentation efficiency while reducing procedural complexity. At the same time, strategic alliances between equipment suppliers and academic centers are producing the real-world evidence necessary to support device claims and foster clinician confidence. Companies that maintain robust training programs and rapid service response capabilities strengthen their relationships with high-volume centers and ambulatory surgical facilities.
Additionally, differentiation is emerging through lifecycle support offerings, such as consumable supply assurance, preventative maintenance plans, and digital platforms that track utilization and outcomes. New entrants that bring disruptive materials or single-use solutions must demonstrate clear clinical and economic advantages to overcome incumbent familiarity and existing service contracts. In this environment, successful players will be those that combine product innovation with demonstrable clinical value and a dependable customer experience across procurement, training, and maintenance channels.
Actionable recommendations for manufacturers and healthcare providers to align innovation, supply resilience, clinical evidence, and service models to accelerate adoption and reduce risk
Industry leaders should pursue a coordinated approach that aligns product innovation with pragmatic commercialization and supply resilience. First, accelerating investments in minimally invasive visualization and fragmentation technologies will address clinician demand for precision and reduced procedure times while supporting outpatient care pathways. Second, building regional supply chain redundancy and exploring nearshore assembly or local partnerships can mitigate tariff and logistics risks, preserving continuity for high-volume customers. Third, prioritizing clinical evidence generation through registries and post-market studies will strengthen adoption and reimbursement discussions, and it will also create defensible differentiation that supports premium pricing.
Furthermore, companies should expand their service footprints to include integrated training, remote support, and predictive maintenance offerings that reduce downtime for end-users. Commercial teams must also refine channel strategies to balance direct relationships with distributors and to leverage online procurement platforms where appropriate, ensuring rapid replenishment and transparent pricing. Finally, aligning product portfolios to the specific needs of Ambulatory Surgical Centers, Clinics, and Hospitals-while accounting for stone-type treatment differences and procedure modality preferences-will enable more targeted sales and marketing investments and improve customer retention.
Transparent research methodology detailing how primary interviews, clinical literature review, device specification analysis, and expert validation were combined to inform findings
The research underpinning this analysis combined primary and secondary methods to ensure balanced, evidence-based conclusions. Primary inputs included structured interviews with practicing urologists, device procurement managers, and clinical engineers to capture firsthand perspectives on device performance, procedural preferences, and procurement constraints. These qualitative insights were triangulated with secondary sources, such as peer-reviewed clinical literature, regulatory filings, and publicly available health system procurement policies, to validate trends and identify emerging areas of clinical interest.
Analysts also examined device specifications, product roadmaps, and patent data to assess technological trajectories. Where possible, real-world clinical outcomes and post-market safety communications were reviewed to understand performance in diverse care settings. Throughout the process, emphasis was placed on ensuring data integrity and avoiding single-source dependency, and findings were iteratively reviewed by clinical advisors to ensure practical relevance and methodological rigor.
Concluding synthesis of how clinical innovation, care model evolution, and operational resilience converge to define future success in kidney stone retrieval
In conclusion, the kidney stone retrieval landscape is undergoing a steady evolution driven by a combination of technological refinement, shifting care models, and heightened expectations for efficiency and patient outcomes. Innovations in ureteroscope design, laser and lithotripsy modalities, and adjunctive retrieval tools are enabling clinicians to treat increasingly complex stone burdens with lower morbidity. Meanwhile, healthcare providers and payers are prioritizing solutions that support same-day care, predictable outcomes, and manageable service requirements.
Looking ahead, success for device manufacturers and health systems will depend on aligning product design with clinician workflow, investing in credible clinical evidence, and building resilient supply chains that can adapt to regional policy shifts and tariff pressures. Organizations that execute on these dimensions while maintaining a relentless focus on customer support and total procedural value will be best positioned to lead in this evolving environment.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Growing adoption of single-use digital ureteroscopes for reduced cross-contamination risk in kidney stone retrieval devices
- 5.2. Emergence of next-generation nitinol stone retrieval baskets with improved flexibility for accessing challenging renal calyces
- 5.3. Advancements in robotic-assisted percutaneous nephrolithotomy for enhanced precision and reduced patient recovery time
- 5.4. Integration of real-time AI-driven imaging algorithms to optimize targeting and removal of complex renal calculi
- 5.5. Development of bioabsorbable stone extraction sheaths to minimize ureteral trauma and postoperative complications
- 5.6. Miniaturization of flexible endoscopic devices enabling ultra-thin access channels for pediatric stone management
- 5.7. Shift towards value-based procurement of cost-effective disposable lithotripters in hospital urology departments
- 5.8. Collaborative innovations between industry and academic centers in designing smart baskets with pressure sensors for improved extraction feedback
- 5.9. Impact of evolving European MDR regulations on the design and clinical evaluation of kidney stone retrieval instruments
- 5.10. Surge in demand for outpatient lithotripsy suites driving portable and handheld retrieval device innovations
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Kidney Stone Retrieval Devices Market, by Product Type
- 8.1. Lithotripters
- 8.2. Stone Removal Baskets
- 8.3. Ureteral Stents
- 8.4. Ureteroscopes
- 9. Kidney Stone Retrieval Devices Market, by Treatment
- 9.1. Extracorporeal Shock Wave Lithotripsy
- 9.2. Percutaneous Nephrolithotomy
- 9.3. Ureteroscopy
- 10. Kidney Stone Retrieval Devices Market, by Treatment Modality
- 10.1. Minimally Invasive Procedures
- 10.2. Non-Invasive Procedures
- 10.3. Open/Conventional Surgeries
- 11. Kidney Stone Retrieval Devices Market, by Stone Type
- 11.1. Calcium Stones
- 11.2. Cystine Stones
- 11.3. Struvite Stones
- 11.4. Uric Acid Stones
- 12. Kidney Stone Retrieval Devices Market, by End User
- 12.1. Ambulatory Surgical Centers
- 12.2. Clinics
- 12.3. Hospitals
- 13. Kidney Stone Retrieval Devices Market, by Distribution Channel
- 13.1. Offline
- 13.2. Online
- 14. Kidney Stone Retrieval Devices Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Kidney Stone Retrieval Devices Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Kidney Stone Retrieval Devices Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Boston Scientific Corporation
- 17.3.2. KARL STORZ SE & Co. KG
- 17.3.3. Olympus Corporation
- 17.3.4. Cook Medical LLC
- 17.3.5. Stryker Corporation
- 17.3.6. Richard Wolf GmbH
- 17.3.7. Teleflex Incorporated
- 17.3.8. Medtronic plc
- 17.3.9. CONMED Corporation
- 17.3.10. Coloplast A/S
- 17.3.11. Becton, Dickinson and Company
- 17.3.12. Siemens Healthineers AG
- 17.3.13. Quanta System S.p.A.
- 17.3.14. Walz Elektronik GmbH
- 17.3.15. MED-Fibers, Inc
- 17.3.16. Cardinal Health, Inc.
- 17.3.17. DCC plc
- 17.3.18. STORZ MEDICAL AG
- 17.3.19. Stryker Corporation
- 17.3.20. Allengers Medical Systems Limited
- 17.3.21. Dornier MedTech GmbH
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
